E-Mail
SAN ANTONIO (June 30, 2021) In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.
Among the 131 patients studied, 94% developed antibodies to the coronavirus. Seven high-risk patients did not. We could not find any antibodies against the virus in those patients, said Dimpy P. Shah, MD, PhD, of the Mays Cancer Center, home to UT Health San Antonio MD Anderson. That has implications for the future. Should we provide a third dose of vaccine after cancer therapy has completed in certain high-risk patients?
UT Health San Antonio gets $6 million grant for DNA cancer research from state agency expressnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from expressnews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Dr. Shenghui Wu, faculty researcher at The University of Texas Health Science Center at San Antonio, led an analysis of bladder cancer incidence and five-year survival, comparing cases in South. view more
Credit: The University of Texas Health Science Center at San Antonio
Bladder cancer is more aggressive and more advanced in South Texas residents than in many parts of the country, a study by the Mays Cancer Center, home to UT Health San Antonio MD Anderson, indicates.
The disease is also deadlier in Latinos and women, regardless of where they live nationwide, according to the research.
The team from The University of Texas Health Science Center at San Antonio (UT Health San Antonio), which includes the Mays Cancer Center, compared bladder cancer cases in the Texas Cancer Registry with cases in the Surveillance, Epidemiology and End Results (SEER) Program. SEER, which collects data on cancer cases from various locations and sources across the U.S.,
UT Health San Antonio lands half of CPRIT s latest state cancer funding - San Antonio Business Journal bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ATLANTA, Jan. 13, 2021 /PRNewswire/ OncoLens, a pioneer in tumor board and cancer treatment planning solutions, announced today that it has raised a $7.25 million Series A investment from BIP Capital, Martin Ventures, and SeedToB Capital, a new healthcare artificial intelligence (AI) venture fund launched by former Jvion Co-founders Shantanu Nigam and Ritesh Sharma.
OncoLens brings collaborative and personalized treatment planning to the cancer patient through data integration and decision support. It helps cancer programs and their multidisciplinary teams of specialists collaborate effectively while easily aggregating patient-specific data in a HIPAA-compliant manner across different EMR/clinical/genetics information systems. Patient-specific clinical trials at a facility or its affiliates, NCCN/ASCO guidelines, and the latest research are also automatically identified for each case to support the care team in making the best decision f